Progestin-primed ovarian stimulation.

Autors de IIS La Fe

• Juan Manuel Gilés Jiménez

  Autor

• Juan Antonio García Velasco

  Autor

Autors aliens a IIS La Fe

• Cruz, Fabio

Grups d'Investigació

• Endocrinología Reproductiva e Infertilidad

  Leader

  José Remohí Giménez

Abstract

PURPOSE OF REVIEW: The use of progestins as pituitary suppressors has increased progressively, along with more detailed indications for their use, thereby consolidating an alternative approach to the personalization of ovarian stimulation. RECENT FINDINGS: Based on the ability of progesterone to inhibit ovulation, progestins have been used in ovarian stimulation (OS) follicular protocols to prevent a luteinizing hormone surge in patients undergoing in vitro fertilization (IVF), as an alternative to gonadotropin-releasing hormone (GnRH) analogue administration. This review explores the different types of progestogen protocols and their efficacy depending on the type of population or reproductive procedure in which they are administered and in comparison with that of GnRH analogues. Their effect on oocytes and embryos and their safety and cost-effectiveness are also analyzed. SUMMARY: Progestins have proven their effectiveness as a gonadotropin adjuvant in terms of ovarian response, reproductive outcome, and safety. In addition, they offer the convenience of oral administration and a lower cost than GnRH analogues. Whereas oocytes or embryos should be vitrified as it displaces the receptive period with the consequent asynchrony between embryo and endometrium. The evidence endorses progestins as a more friendly approach to OS, especially when frozen-thawed embryo transfer is planned.

Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

• freeze-all; in vitro fertilization; ovarian stimulation; pituitary suppressor; progestin